Please assess the completion status of the following clinical trial:

Trial Title: EASSI - Evaluation of the Safety of Self-Administration With Icatibant

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Each patient must meet the following criteria to be enrolled in this study.~1. Males and females 18 years of age at the time of informed consent~2. Documented diagnosis of HAE Type I or II based on ALL of the following criteria:~   * Family and/or medical history~  * Characteristic attack manifestations, recurrent attacks~  * Historical functional C1-INH \<50% normal values~3. Women of childbearing potential must use consistently and correctly a highly effective, adequate method of birth control (failure rate less than 1% per year) - sexual abstinence or have a vasectomised partner during the duration of the study. Hormonal contraception can be continued if verified by a physician that it doesn't affect the course of HAE attacks.~4. Mental and physical condition allowing patients to complete baseline assessment, to self-administer icatibant and to follow other study procedures.~5. Ability to provide signed written informed consent after all aspects of the study have been explained and discussed with the patient.~Exclusion Criteria:~Patients who meet any of the following criteria will be excluded from the study.~1. Participation in a clinical trial of another investigational medicinal product within the past month (except a previous icatibant study).~2. Diagnosis of angioedema other than Type I or Type II HAE.~3. Evidence of symptomatic coronary artery disease based on medical history, in particular, unstable angina pectoris or severe coronary heart disease.~4. Congestive heart failure (NYHA Class 3 and 4).~5. Stroke within the past 6 months.~6. Treatment with angiotensin converting enzyme (ACE) inhibitor.~7. Pregnancy and/or breast-feeding.~8. In the opinion of the investigator: mental condition rendering the patient unable to understand the nature, scope and possible consequences of the study.~9. In the opinion of the investigator: unlikely to comply with the protocol, for example, uncooperative attitude, inability to return for follow-up visits, or unlikely to complete the study for any reason.~10. In the opinion of the investigator: inability to manage study medication or self-administration of an injection.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Icatibant- Naive Treatment Phase (Type: EXPERIMENTAL): Single subcutaneous injection of icatibant, 30 mg
- icatibant- Self administration Phase (Type: EXPERIMENTAL): Single subcutaneous injection of icatibant, 30 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).